Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment.

ABSTRACT:

Purpose

The safety and efficacy of subcutaneous immune globulin 20% (human) solution (Ig20Gly) were demonstrated in clinical trials. However, real-world evidence of the tolerability of self-administered Ig20Gly in elderly patients is lacking. We describe real-world patterns of Ig20Gly usage for 12 months in patients with primary immunodeficiency diseases (PIDD) in the USA.

Methods

This retrospective chart review of longitudinal data from 2 centers included patients aged ≥ 2 years with PIDD. Ig20Gly administration parameters, tolerability, and usage patterns were assessed at initial and subsequent 6- and 12-month infusions.

Results

Of 47 enrolled patients, 30 (63.8%) received immunoglobulin replacement therapy (IGRT) within 12 months before starting Ig20Gly, and 17 (36

SUBMITTER: Rosenbach K 

PROVIDER: S-EPMC10275800 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature